Growth factor release from amylopectin hydrogel based on copper coordination.
This paper describes a biodegradable hydrogel matrix releasing basic fibroblast growth factor (bFGF) on the basis of protein metal coordination with the protein drug. The biodegradable hydrogel was prepared from amylopectin by its crosslinking with ethylene glycol diglycidyl ether, followed by introduction of diethylenetriaminepentaacetic acid (DTPA) residues for copper chelation. When bFGF was incorporated into the DTPA-introduced amylopectin hydrogel after chelation with Cu2+, an insignificant amount of bFGF was released from the hydrogel in buffered solution, in contrast to that without Cu2+ chelation. An increased ionic strength in the solution did not affect the bFGF release, indicating the occurrence of coordinate bonding of bFGF to the DTPA-introduced hydrogel through Cu2+ chelation. An implantation study with 125I-labeled amylopectin hydrogels demonstrated that they underwent degradation in the back subcutis of mice. Cu2+ chelation of hydrogels enabled bFGF to remain in the mouse back for a long time period, irrespective of DTPA introduction. However, DTPA residues were necessary to induce significant neovascularization by the Cu2+-chelating hydrogels incorporating bFGF. The DTPA-introduced amylopectin prevented Cu2+-induced deactivation of bFGF, again in marked contrast to DTPA-free amylopectin. It was concluded that biologically active bFGF could be incorporated to DTPA-introduced amylopectin through Cu2+ chelation in a stabilized state and was released as a result of hydrogel biodegradation, resulting in prolonged neovascularization.
Tabata
Y
Y
Research Center for Biomedical Engineering, Kyoto University, 53 Kawahara-cho Shogoin, Sakyo-ku, Kyoto 606-8507, Japan.
Matsui
Y
Y
Ikada
Y
Y
D000687:Amylopectin / Q000008:administration & dosage / Q000737:chemistry* / Q000493:pharmacokinetics*; D000818:Animals; D002614:Chelating Agents / Q000737:chemistry / Q000493:pharmacokinetics; D002626:Chemistry, Pharmaceutical; D002846:Chromatography, Affinity; D002851:Chromatography, High Pressure Liquid; D003300:Copper / Q000008:administration & dosage / Q000737:chemistry* / Q000493:pharmacokinetics*; D003432:Cross-Linking Reagents / Q000737:chemistry / Q000493:pharmacokinetics; D016222:Fibroblast Growth Factor 2 / Q000008:administration & dosage / Q000737:chemistry* / Q000493:pharmacokinetics*; D006493:Heparin / Q000737:chemistry; D020100:Hydrogels / Q000008:administration & dosage / Q000737:chemistry* / Q000493:pharmacokinetics*; D051379:Mice; D018919:Neovascularization, Physiologic / Q000187:drug effects; D004369:Pentetic Acid / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics
D002614:Chelating Agents; D003432:Cross-Linking Reagents; D020100:Hydrogels; D016222:Fibroblast Growth Factor 2; D003300:Copper; D004369:Pentetic Acid; D006493:Heparin; D000687:Amylopectin